

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Advances in understanding the... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-297/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-297" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy" />
    
            <meta name="og:title" content="F1000Research Article: Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy.">
            <meta name="og:description" content="Read the latest article version by Lama Ghazi, Paul Drawz, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="10445">
            <meta name="article-id" content="9692">
            <meta name="dc.title" content="Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy">
            <meta name="dc.description" content="The renin-angiotensin-aldosterone system (RAAS) plays a fundamental role in the physiology of blood pressure control and the pathophysiology of hypertension (HTN) with effects on vascular tone, sodium retention, oxidative stress, fibrosis, sympathetic tone, and inflammation. Fortunately, RAAS blocking agents have been available to treat HTN since the 1970s and newer medications are being developed. In this review, we will (1) examine new anti-hypertensive medications affecting the RAAS, (2) evaluate recent studies that help provide a better understanding of which patients may be more likely to benefit from RAAS blockade, and (3) review three recent pivotal randomized trials that involve newer RAAS blocking agents and inform clinical practice.">
            <meta name="dc.subject" content="renin-angiotensin-aldosterone system, hypertension, blood pressure control, anti-hypertensive drugs, blocking agents">
            <meta name="dc.creator" content="Ghazi, Lama">
            <meta name="dc.creator" content="Drawz, Paul">
            <meta name="dc.date" content="2017/03/21">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.9692.1">
            <meta name="dc.source" content="F1000Research 2017 6:297">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="renin-angiotensin-aldosterone system ">
            <meta name="prism.keyword" content=" hypertension ">
            <meta name="prism.keyword" content=" blood pressure control ">
            <meta name="prism.keyword" content=" anti-hypertensive drugs ">
            <meta name="prism.keyword" content=" blocking agents">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/03/21">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="297">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.9692.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-297">
            <meta name="citation_title" content="Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy">
            <meta name="citation_abstract" content="The renin-angiotensin-aldosterone system (RAAS) plays a fundamental role in the physiology of blood pressure control and the pathophysiology of hypertension (HTN) with effects on vascular tone, sodium retention, oxidative stress, fibrosis, sympathetic tone, and inflammation. Fortunately, RAAS blocking agents have been available to treat HTN since the 1970s and newer medications are being developed. In this review, we will (1) examine new anti-hypertensive medications affecting the RAAS, (2) evaluate recent studies that help provide a better understanding of which patients may be more likely to benefit from RAAS blockade, and (3) review three recent pivotal randomized trials that involve newer RAAS blocking agents and inform clinical practice.">
            <meta name="citation_description" content="The renin-angiotensin-aldosterone system (RAAS) plays a fundamental role in the physiology of blood pressure control and the pathophysiology of hypertension (HTN) with effects on vascular tone, sodium retention, oxidative stress, fibrosis, sympathetic tone, and inflammation. Fortunately, RAAS blocking agents have been available to treat HTN since the 1970s and newer medications are being developed. In this review, we will (1) examine new anti-hypertensive medications affecting the RAAS, (2) evaluate recent studies that help provide a better understanding of which patients may be more likely to benefit from RAAS blockade, and (3) review three recent pivotal randomized trials that involve newer RAAS blocking agents and inform clinical practice.">
            <meta name="citation_keywords" content="renin-angiotensin-aldosterone system, hypertension, blood pressure control, anti-hypertensive drugs, blocking agents">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Lama Ghazi">
            <meta name="citation_author_institution" content="Division of Renal Disease and Hypertension, Department of Medicine, University of Minnesota, Minnesota, MN, USA">
            <meta name="citation_author" content="Paul Drawz">
            <meta name="citation_author_institution" content="Division of Renal Disease and Hypertension, Department of Medicine, University of Minnesota, Minnesota, MN, USA">
            <meta name="citation_publication_date" content="2017/03/21">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="297">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.9692.1">
            <meta name="citation_firstpage" content="297">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-297/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-297.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=10445 /> <input type=hidden id=articleId name=articleId value=9692 /> <input type=hidden id=xmlUrl value="/articles/6-297/v1/xml"/> <input type=hidden id=xmlFileName value="-6-297-v1.xml"> <input type=hidden id=article_uuid value=3e801393-96ec-496a-8e79-0f7581b68a78 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.9692.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.9692.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-297"
  },
  "headline": "Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent...",
  "datePublished": "2017-03-21T09:31:41",
  "dateModified": "2017-03-21T09:31:41",
  "author": [
    {
      "@type": "Person",
      "name": "Lama Ghazi"
    },    {
      "@type": "Person",
      "name": "Paul Drawz"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The renin-angiotensin-aldosterone system (RAAS) plays a fundamental role in the physiology of blood pressure control and the pathophysiology of hypertension (HTN) with effects on vascular tone, sodium retention, oxidative stress, fibrosis, sympathetic tone, and inflammation. Fortunately, RAAS blocking agents have been available to treat HTN since the 1970s and newer medications are being developed. In this review, we will (1) examine new anti-hypertensive medications affecting the RAAS, (2) evaluate recent studies that help provide a better understanding of which patients may be more likely to benefit from RAAS blockade, and (3) review three recent pivotal randomized trials that involve newer RAAS blocking agents and inform clinical practice."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-297.html",
            "name": "Advances in understanding the renin-angiotensin-aldosterone system..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Advances in understanding the renin-angiotensin-aldosterone system... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=10445 data-id=9692 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9692.1" data-recommended="" data-doi="10.12688/f1000research.9692.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-297/v1/pdf?article_uuid=3e801393-96ec-496a-8e79-0f7581b68a78" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-9692-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-9692-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-9692-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Ghazi L and Drawz P. Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):297 (<a class=new-orange href="https://doi.org/10.12688/f1000research.9692.1" target=_blank>https://doi.org/10.12688/f1000research.9692.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-9692-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=9692 id=track-article-signin-9692 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9692?target=/articles/6-297.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10445 /> <input name=articleId type=hidden value=9692 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Lama Ghazi,&nbsp;</span><span class=""><a href="mailto:pedrawz00@yahoo.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Paul Drawz</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Lama Ghazi,&nbsp;</span><span class=""><a href="mailto:pedrawz00@yahoo.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Paul Drawz</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 21 Mar 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.9692.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Division of Renal Disease and Hypertension, Department of Medicine, University of Minnesota, Minnesota, MN, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=21030-20755></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=21029-20754></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=21031-20756></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The renin-angiotensin-aldosterone system (RAAS) plays a fundamental role in the physiology of blood pressure control and the pathophysiology of hypertension (HTN) with effects on vascular tone, sodium retention, oxidative stress, fibrosis, sympathetic tone, and inflammation. Fortunately, RAAS blocking agents have been available to treat HTN since the 1970s and newer medications are being developed. In this review, we will (1) examine new anti-hypertensive medications affecting the RAAS, (2) evaluate recent studies that help provide a better understanding of which patients may be more likely to benefit from RAAS blockade, and (3) review three recent pivotal randomized trials that involve newer RAAS blocking agents and inform clinical practice. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> renin-angiotensin-aldosterone system, hypertension, blood pressure control, anti-hypertensive drugs, blocking agents </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Paul Drawz (<a href="mailto:pedrawz00@yahoo.com">pedrawz00@yahoo.com</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Paul Drawz </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Ghazi L and Drawz P. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the <a href="http://creativecommons.org/publicdomain/zero/1.0/" target=_blank data-test-id=box-data-licence-link>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication). </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Ghazi L and Drawz P. Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):297 (<a href="https://doi.org/10.12688/f1000research.9692.1" target=_blank>https://doi.org/10.12688/f1000research.9692.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 21 Mar 2017, <b>6</b>(F1000 Faculty Rev):297 (<a href="https://doi.org/10.12688/f1000research.9692.1" target=_blank>https://doi.org/10.12688/f1000research.9692.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 21 Mar 2017, <b>6</b>(F1000 Faculty Rev):297 (<a href="https://doi.org/10.12688/f1000research.9692.1" target=_blank>https://doi.org/10.12688/f1000research.9692.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d1264e149>New and existing anti-hypertensive drugs affecting the renin-angiotensin-aldosterone system</h2><p class="" id=d1264e152>There are well-established drugs that interfere with the renin-angiotensin-aldosterone system (RAAS) at several sites, including (1) angiotensin-converting enzyme inhibitors (ACEIs), (2) angiotensin II type I (AT<sub>1</sub>) receptor blockers (ARBs), (3) direct renin inhibitors (DRIs), (4) mineralocorticoid receptor antagonists (MRAs), and even (5) beta blockers, the last of which may be considered partial inhibitors (<a href="#f1">Figure 1</a>)<sup><a href="#ref-1">1</a>–<a href="#ref-4">4</a></sup>. In this section, we briefly review trials demonstrating benefits of ACEIs/ARBs and then discuss recent advances and newer agents that block the RAAS at different sites.</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/10445/dac16b6e-0c2b-4b17-b543-49ef9a0b080c_figure1.gif"><img alt="dac16b6e-0c2b-4b17-b543-49ef9a0b080c_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/10445/dac16b6e-0c2b-4b17-b543-49ef9a0b080c_figure1.gif"></a><div class=caption><h3>Figure 1. New and existing drugs interfering with the renin-angiotensin (Ang) system cascade.</h3><p id=d1264e178>Classically, interference occurs at the level of renin, angiotensin-converting enzyme (ACE), the Ang II type 1 (AT<sub>1</sub>) receptor (R), or the mineralocorticoid receptor (MR), with renin inhibitors, ACE inhibitors, AT<sub>1</sub> receptor blockers (ARBs), or MR antagonists. Novel enzyme inhibitors now target aminopeptidase A (APA), which generates Ang III (=Ang-[1–7]) from Ang II (=Ang-[1–8]), or aldosterone synthase (CYP11B2). Activators of ACE2 (XNT and diminazene), which generates Ang-(1–7) from Ang II, were recently found to act equally well in ACE2 knockout animals, thus questioning their mechanism of action. Numerous agonists for both the AT<sub>2</sub> receptor and Mas receptor are being developed. Aminopeptidase N (APN) degrades Ang III to Ang IV (=Ang-[3–8]), which may act on the AT<sub>4</sub> receptor, also known as insulin-regulated aminopeptidase (IRAP). Figure reprinted with permission of the American Heart Association<sup><a href="#ref-57">57</a></sup>.</p></div></div><div class=section><a name=d1264e201 class=n-a></a><h3 class=section-title>Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers</h3><p class="" id=d1264e206>ACEIs and ARBs have been the cornerstone of RAAS inhibition for years and are key therapeutic options in patients with hypertension (HTN), reducing cardiovascular morbidity and mortality and improving renal outcomes. In the HOPE (Heart Outcomes Prevention Evaluation)<sup><a href="#ref-5">5</a></sup>, MICRO-HOPE (The Microalbuminuria, Cardiovascular, and Renal Outcomes in HOPE)<sup><a href="#ref-6">6</a></sup>, EUROPA (European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease)<sup><a href="#ref-7">7</a></sup>, SOLVD (Studies of Left Ventricular Dysfunction)<sup><a href="#ref-8">8</a></sup>, and Captopril Prevention Project<sup><a href="#ref-9">9</a></sup> studies, ACEIs were beneficial in reducing rates of death, myocardial infarction, stroke, coronary revascularization, cardiac arrest, and heart failure, complications related to diabetes and heart failure. Both the RENAAL<sup><a href="#ref-10">10</a></sup> and IDNT<sup><a href="#ref-11">11</a></sup> trials demonstrated a renoprotective effect of RAAS inhibition in nephropathy due to diabetes. ACEIs and ARBs are considered to be equally beneficial on the basis of studies such as ONTARGET<sup><a href="#ref-12">12</a></sup>, which compared telmisartan and ramipril, and DETAIL<sup><a href="#ref-13">13</a></sup>, which compared telmisartan with enalapril and found no difference in progression of diabetic nephropathy.</p><p class="" id=d1264e246>Azilsartan, a novel ARB, has been shown to have superior efficacy in reducing blood pressure (BP) when compared with olmesartan or valsartan<sup><a href="#ref-14">14</a>–<a href="#ref-16">16</a></sup>. Azilsartan 80 mg reduces BP more efficaciously than the optimal and highest tolerated dosage of both olmesartan (40 mg) and valsartan (320 mg) using 24-hour ambulatory BP monitoring and without increase in adverse effects<sup><a href="#ref-14">14</a></sup>. A recent analysis of a German registry confirmed these results; among 3,849 patients with essential HTN, 61% of patients who initiated therapy with azilsartan achieved a BP target of less than 140/90 mmHg compared with 56% of those who were started on an ACEI<sup><a href="#ref-17">17</a></sup>. Azilsartan may be more effective at lowering BP because of its more potent ability to block AT<sub>1</sub> receptors<sup><a href="#ref-18">18</a></sup>. However, only a prospective, randomized, dose-escalation study can truly test whether azilsartan is superior to other ARBs at lowering BP.</p></div><div class=section><a name=d1264e272 class=n-a></a><h3 class=section-title>Direct renin inhibitors</h3><p class="" id=d1264e277>Renin secretion, a rate-limiting step, is the first step of the RAAS cascade. Renin has a unique specificity for its substrate angiotensin. Inhibition of renin provides an attractive option to inhibit the RAAS from its origin. The development of DRI started more than 30 years ago<sup><a href="#ref-19">19</a></sup>, but there were issues with potency, bioavailability, and cost. Currently, aliskiren is the only approved DRI for use in HTN<sup><a href="#ref-20">20</a></sup>, and a significant BP reduction has been demonstrated in patients with essential HTN<sup><a href="#ref-21">21</a>,<a href="#ref-22">22</a></sup>. Aliskiren is well tolerated and has a similar dose-dependent BP reduction in hypertensive patients as ARBs and a safety profile similar to that of placebo<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>.</p><p class="" id=d1264e302>However, several recent studies have shown either no benefit or even harmful effects of aliskiren in certain populations. The ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints)<sup><a href="#ref-25">25</a></sup> trial randomly assigned patients with type 2 diabetes and chronic kidney disease (CKD) or with cardiovascular disease (or with all three) already receiving an ACEI or ARB to aliskiren or placebo. Although there was a lower BP in the aliskiren arm, there was no reduction in the primary composite outcome, which included cardiovascular and renal events and mortality (hazard ratio [HR] 1.08, 95% confidence interval [CI] 0.98–1.20). In the ATMOSPHERE<sup><a href="#ref-26">26</a></sup> trial (Aliskiren Trial to Minimize Outcomes in Patients with Heart failure), the addition of aliskiren to enalapril in patients with chronic heart failure was not associated with reduction in adverse outcomes (see “Recent clinical trials” section for details). Similarly, no improvement in coronary atherosclerosis in pre-hypertensive patients (AQUARIUS)<sup><a href="#ref-27">27</a></sup> or improvement in cardiovascular outcomes in patients hospitalized with heart failure (ASTRONAUT)<sup><a href="#ref-28">28</a></sup> was seen with aliskiren compared with placebo. Given the lack of demonstrated benefit and increased rates of adverse events such as hyperkalemia, hypotension, and renal impairment as seen in ASTRONAUT when combined with ACEIs or ARBs, the current use of aliskiren is limited<sup><a href="#ref-28">28</a></sup>.</p></div><div class=section><a name=d1264e327 class=n-a></a><h3 class=section-title>Mineralocorticoid receptor antagonists</h3><p class="" id=d1264e332>MRAs competitively inhibit mineralocorticoid receptors and decrease the number of epithelial sodium channels in the distal renal tubule<sup><a href="#ref-29">29</a></sup>. Spironolactone, an MRA, has long been used for the treatment of HTN; however, its non-specificity for mineralocorticoid receptors manifests as anti-androgenic and progestational effects<sup><a href="#ref-30">30</a>,<a href="#ref-31">31</a></sup>. Spironolactone was found to be the most effective add-on anti-hypertensive drug when compared with doxazosin and bisoprolol in treating resistant HTN in the PATHWAY-2 trial<sup><a href="#ref-32">32</a></sup>. This trial supports the important role of sodium retention in resistant HTN. Eplerenone, an MRA with lower affinity to progesterone and androgen receptors than spironolactone<sup><a href="#ref-29">29</a></sup>, has been shown to be efficacious even using ambulatory monitoring studies<sup><a href="#ref-33">33</a></sup> and safe in the management of HTN. When compared with enalapril<sup><a href="#ref-34">34</a></sup>, losartan<sup><a href="#ref-35">35</a></sup>, and amlodipine<sup><a href="#ref-36">36</a></sup>, eplerenone monotherapy was as efficacious in treating HTN.</p><p class="" id=d1264e371>Currently, third- and fourth-generation MRAs are being developed to have the potency of spironolactone and the selectivity of eplerenone<sup><a href="#ref-37">37</a></sup>. Finerenone, a novel non-steroidal MRA, has a greater affinity to the mineralocorticoid receptor than does eplerenone<sup><a href="#ref-38">38</a></sup> and greater selectivity than does spironolactone<sup><a href="#ref-39">39</a></sup>. The Mineralocorticoid Receptor Antagonist Tolerability Study (ARTS) showed that finerenone (2.5–10 mg per day), in patients with CKD and albuminuria, decreased albuminuria with lower rates of hyperkalemia compared with spironolactone<sup><a href="#ref-40">40</a></sup>. With the recent development of patiromer, a non-absorbed potassium binder, a safe option for the treatment of chronic hyperkalemia is available, maintaining and using RAAS inhibitors including spironolactone, in CKD and heart failure<sup><a href="#ref-41">41</a></sup>. Patiromer has also been shown to decrease potassium and aldosterone levels in patients with CKD and hyperkalemia on RAAS inhibitors independent of renin activity<sup><a href="#ref-42">42</a></sup>. The recent ARTS-DN (Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy) study demonstrated greater reduction in albuminuria with the addition of finerenone to ACEI or ARB in patients with diabetic nephropathy compared with placebo (see “Recent clinical trials” section for details)<sup><a href="#ref-43">43</a>,<a href="#ref-44">44</a></sup>.</p></div><div class=section><a name=d1264e407 class=n-a></a><h3 class=section-title>Aldosterone synthase inhibitors</h3><p class="" id=d1264e412>Another way of blocking the effects of mineralocorticoid receptor activation is to inhibit aldosterone formation. LCI699 is a potent first-in-class aldosterone synthase inhibitor. In patients with primary aldosteronism, LCI699 (up to 1.0 mg twice a day) caused modest reduction in 24-hour systolic BP (SBP) and office SBP compared with placebo<sup><a href="#ref-45">45</a></sup>. One mg of LCI699 was not superior to eplerenone 50 mg in reducing ambulatory SBP in patients with stage 1 or 2 HTN<sup><a href="#ref-46">46</a></sup>. LCI699 significantly lowered office and ambulatory BP in patients with primary HTN, but 20% of the patients on LCI699 developed blunted cortisol release<sup><a href="#ref-46">46</a></sup>. Because of this non-specificity, the development of LCI699 has been stopped in favor of developing more specific inhibitors.</p></div><div class=section><a name=d1264e428 class=n-a></a><h3 class=section-title>Aminopeptidase A inhibitor</h3><p class="" id=d1264e433>Functional RAAS may be present in the brain<sup><a href="#ref-47">47</a></sup>, and several animal models have demonstrated that hyperactivity of brain RAAS may contribute to HTN<sup><a href="#ref-48">48</a>,<a href="#ref-49">49</a></sup>. Brain aminopeptidase A (APA) converts angiotensin II to angiotensin III. APA inhibition by EC33 has been shown to be a novel anti-hypertensive agent in animals<sup><a href="#ref-50">50</a>–<a href="#ref-52">52</a></sup>. QGC001, an orally active prodrug of EC33, was tolerated in healthy normotensive human males but with no changes in renin, aldosterone, BP, or heart rate<sup><a href="#ref-53">53</a>–<a href="#ref-56">56</a></sup>. This study demonstrates that QGC001, the first drug in its class, can be safely administered to humans, but further studies are required to assess the safety and efficacy of QGC001 in patients with HTN. Additional research on novel ways to block the RAAS, including development of prorenin blockade, gene- and vaccine-based strategies, and targeting ACE2, is being developed but has not yet translated into the clinic<sup><a href="#ref-57">57</a>,<a href="#ref-58">58</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1264e472>Predictors of renin-angiotensin-aldosterone system blockade response in patients with hypertension</h2><p class="" id=d1264e475>In this section, we will review recent advances in understanding characteristics that may predispose patients to a greater response to RAAS blockade.</p><div class=section><a name=d1264e478 class=n-a></a><h3 class=section-title>Plasma renin activity</h3><p class="" id=d1264e483>Patients with high plasma renin activity (PRA) respond well to RAAS blockers, some of which suppress renin release<sup><a href="#ref-59">59</a>–<a href="#ref-62">62</a></sup>. For example, patients with elevated renin had a greater BP-lowering response to atenolol, an agent that suppresses renin release, than a diuretic<sup><a href="#ref-60">60</a>,<a href="#ref-61">61</a></sup>. In contrast, in patients with low renin, anti-renin drugs (including aliskiren) may exert a pressor effect<sup><a href="#ref-61">61</a>,<a href="#ref-63">63</a></sup>.</p><p class="" id=d1264e507>Using PRA levels as a treatment strategy is currently being tested as a way to improve BP control<sup><a href="#ref-64">64</a>,<a href="#ref-65">65</a></sup>. Egan <i>et al</i>. showed that, in patients with uncontrolled HTN, ambulatory PRA provides information on the extracellular fluid and plasma volume<sup><a href="#ref-64">64</a></sup>. In their trial, a “renin test-guided therapeutic (RTGT) algorithm” targeted RAAS blockers to patients with high renin. The RTGT resulted in greater reduction in SBP compared with clinical HTN specialist care (–29.1 ± 3.2 mmHg versus –19.2 ± 3.2 mmHg; <i>P</i> = 0.003). Therefore, it would seem logical to treat hypertensive patients with high PRA with anti-renin-angiotensin drugs as a first choice<sup><a href="#ref-64">64</a></sup>. Although targeting RAAS blockade to patients with high PRA may be an effective BP-lowering strategy, further studies on the effect of RTGT treatment on risk for clinically important end-points are needed before this strategy can be recommended.</p></div><div class=section><a name=d1264e532 class=n-a></a><h3 class=section-title>Salt</h3><p class="" id=d1264e537>Salt plays an important role in BP response to RAAS blockers, although the exact mechanism remains to be elucidated. High salt intake causes volume expansion and BP elevation, which leads to pressure-dependent tissue injury, including renal injury<sup><a href="#ref-66">66</a>–<a href="#ref-70">70</a></sup>. RAAS inhibitors reverse the salt-induced renal injury in spontaneous hypertensive rats<sup><a href="#ref-71">71</a>–<a href="#ref-73">73</a></sup>.</p><p class="" id=d1264e554>Kobori <i>et al</i>. showed that a high-salt diet decreased PRA and enhanced kidney angiotensinogen levels in Dahl-sensitive rats, contributing to HTN<sup><a href="#ref-74">74</a></sup>. An increase in angiotensin II contributes to activation of the mineralocorticoid receptor-dependent intracellular signaling pathway, perhaps via induction of reactive oxygen species, and it has been proposed that mineralocorticoid receptor activation can occur independently of aldosterone in salt-sensitive HTN<sup><a href="#ref-75">75</a>–<a href="#ref-77">77</a></sup>. This has recently been demonstrated in a study of patients with resistant HTN. Ghazi <i>et al</i>. examined predictors of BP response to spironolactone in a retrospective analysis of 79 patients with resistant HTN<sup><a href="#ref-78">78</a></sup>. Patients with high urinary sodium excretion (200 mEq/24 hours) had a significantly greater BP reduction with spironolactone compared with patients with a lower excretion (&lt;200 mEq/24 hours) (<i>P</i> = 0.008). After potential confounders, primary aldosteronism, serum aldosterone concentration, and serum potassium were controlled for, 24-hour urinary sodium excretion remained a significant, independent predictor (<i>P</i> = 0.02) of a favorable BP response, defined as an at least 10 mmHg reduction in office SBP. Despite its limitations, including its retrospective design, not using 24-hour ambulatory BP monitoring, and non-generalizability to the general HTN population with controlled BP, it is the first study to suggest the benefit of MRA in counteracting the effects of high-sodium diet in patients with HTN, irrespectively of their aldosterone status<sup><a href="#ref-78">78</a></sup>. Given the difficulty in modifying patients’ dietary habits, elevated 24-hour urine sodium excretion may be used to identify patients who are more likely to be responsive to spironolactone.</p></div><div class=section><a name=d1264e590 class=n-a></a><h3 class=section-title>Ethnicity</h3><p class="" id=d1264e595>It is well known that African-Americans (AAs) have a different response to RAAS blockers when compared with whites. This might be due to several mechanisms, including salt sensitivity, low renin, and high aldosterone levels, which may be interrelated<sup><a href="#ref-79">79</a>–<a href="#ref-83">83</a></sup>. In ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) and the blood pressure-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA), ACEIs were less effective in reducing BP in AAs compared with whites; however, no racial difference was observed in those randomly assigned to a diuretic<sup><a href="#ref-84">84</a>–<a href="#ref-86">86</a></sup>. This effect is not limited to ACEIs. In a randomized placebo-controlled study in AAs with low renin and poorly controlled HTN, both spironolactone and amiloride lowered BP similarly in AAs and whites<sup><a href="#ref-87">87</a></sup>. However, AAs had a significantly better response to eplerenone than to losartan (ARB), whereas no difference in response between these two agents was found in whites<sup><a href="#ref-88">88</a></sup>. In patients with heart failure treated with spironolactone, AAs exhibit less hyperkalemia compared with whites when treated with MRAs<sup><a href="#ref-89">89</a></sup>.</p><p class="" id=d1264e624>A recent study on patients from New York City’s Health and Hospitals Corporation compared ACEI efficacy to calcium channel blocker (CCB), thiazide diuretics, and beta blockers in AAs. It included a cohort of 25,564 propensity score-matched hypertensive AA patients. ACEIs were associated with a higher risk of primary outcome (myocardial infarction, stroke, and heart failure) compared with CCB (4,506 matched pairs; HR 1.45, 95% CI 1.19–1.77; <i>P</i> = 0.0003), and a higher risk for primary outcome was observed when ACEIs were compared with thiazide diuretics in AAs (5,337 matched pairs; HR 1.65, 95% CI 1.33–2.05; <i>P</i> &lt; 0.0001)<sup><a href="#ref-90">90</a></sup>. A meta-analysis of 13 different trials in the USA and Europe showed that SBP and diastolic BP reduction with ACEI monotherapy was consistently lower among AAs than among whites<sup><a href="#ref-91">91</a></sup>. Therefore, as recommended by the members appointed to the Eighth Joint National Committee (JNC 8), initial anti-hypertensive therapy for the AA population should include a thiazide or CCB.</p></div><div class=section><a name=d1264e643 class=n-a></a><h3 class=section-title>Sex</h3><p class="" id=d1264e648>The RAAS is affected by sex hormones and plays a role in sex-related differences in BP; however, there are no specific guidelines that suggest sex-specific treatment<sup><a href="#ref-57">57</a>,<a href="#ref-92">92</a>–<a href="#ref-94">94</a></sup>. Estrogen attenuates the vasoconstrictor effect of the RAAS by decreasing renin, angiotensin, and nitric oxide synthase, but this attenuation will decrease once women reach menopause<sup><a href="#ref-57">57</a>,<a href="#ref-95">95</a>,<a href="#ref-96">96</a></sup>. Irbesartan, for example, has a greater BP-lowering effect in pre-menopausal women than in men<sup><a href="#ref-97">97</a></sup>. In a retrospective observational study of congestive heart failure (CHF), women had a better survival with ARBs than with ACEIs whether they were hypertensive or not<sup><a href="#ref-98">98</a></sup>. In hypertensive men, their survival was comparable using an ARB or an ACEI. In non-hypertensive men, ACEIs were associated with better survival.</p><p class="" id=d1264e679>More recently, the Identification of the Determinants of the Efficacy of Arterial blood pressure Lowering drugs (IDEAL) trial set out to identify office SBP response to both an ACEI (perindopril) and a diuretic (indapamide) in untreated hypertensive patients (SBP ≥140 and &lt;180 mmHg) between 25 and 70 years of age<sup><a href="#ref-99">99</a></sup>. For the 112 patients included in this cross-over study, the average BP responses were 7.2/4.0 mmHg for indapamide and 6.6/4.2 mmHg for perindopril. The response among women, without distinction among pre- or post-menopausal, was almost two times greater than in men for indapamide (mean effect of –11.5 mmHg for women versus –4.8 mmHg for men; <i>P</i> &lt;0.001) and for perindopril (mean effect of –8.3 mmHg for women versus –4.3 mmHg for men; <i>P</i> = 0.015). Subgroup analysis of the response to indapamide by age revealed that an association was present in women and that there was an increase of the response by 3 mmHg for every 10 years of age (<i>P</i> = 0.024). Therefore, both age and sex were important determinants of BP response in the IDEAL population.</p><p class="" id=d1264e695>BP response to various RAAS blockades is affected by renin, salt, gender, ethnicity, and even age. However, all of those factors are likely interrelated. For instance, AAs have lower renin activity than do whites and have been shown to respond better to atenolol<sup><a href="#ref-62">62</a>,<a href="#ref-86">86</a></sup>. Patients on a low-salt diet have higher renin activity<sup><a href="#ref-57">57</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1264e713>Recent clinical trials</h2><p class="" id=d1264e716>In this final section, we review a few recent pivotal trials of RAAS blockade.</p><div class=section><a name=d1264e719 class=n-a></a><h3 class=section-title>ATMOSPHERE trial</h3><p class="" id=d1264e724>RAAS blockade reduces the risk of death among patients with heart failure with reduced ejection fraction<sup><a href="#ref-8">8</a></sup>. Dual blockade with an ACEI and aliskiren reduced N-terminal prohormone of brain natriuretic peptide (NT-proBNP). Therefore, the ATMOSPHERE trial<sup><a href="#ref-26">26</a></sup> randomly assigned patients in a 1:1:1 fashion to aliskiren 300 mg once daily (n = 2,340), enalapril 5 or 10 mg twice daily (n = 2,336), or enalapril 5 or 10 mg twice daily + aliskiren 300 mg once daily (n = 2,340), and patients were followed-up for 36.6 months (interquartile range of 22.4 to 52.2). ATMOSPHERE included patients at least 18 years of age with chronic symptomatic heart failure (New York Heart Association functional class II–IV), left ventricular ejection fraction of not more than 35%, and an estimated glomerular filtration rate (eGFR) of at least 40 mL/minute per 1.73 m<sup>2</sup>.</p><p class="" id=d1264e738>The Clinical Trials Facilitation Group of the Heads of Medicines Agencies in Europe requested discontinuation of ATMOSPHERE study drugs in diabetic patients following the results of the ALTITUDE and ASTRONAUT trials. Overall, there was no difference in the primary outcome, cardiovascular death, or CHF hospitalization for aliskiren + enalapril versus enalapril (32.9% versus 34.6%; HR 0.93, 95% CI 0.85–1.03; <i>P</i> = 0.17 for superiority) or for aliskiren versus enalapril (33.8% versus 34.6%; HR 0.99, 95% CI 0.90–1.10; <i>P</i> = 0.91 for superiority) (<i>P</i> = 0.018 for non-inferiority; not significant per pre-specified threshold). There were no differences in most of the secondary outcomes, but combination therapy was associated with increased risk for the composite renal outcome (HR 2.2, 95% CI 1.2–3.8). Combination therapy was also associated with increased risk for hypotension and hyperkalemia. In all, ATMOSPHERE indicates that aliskiren is not superior to enalapril either as monotherapy or as combination therapy in patients with heart failure with reduced ejection fraction.</p></div><div class=section><a name=d1264e751 class=n-a></a><h3 class=section-title>ARTS-DN trial</h3><p class="" id=d1264e756>Finerenone is a non-steroidal MRA that is equally efficacious as spironolactone at reducing BNP and albuminuria in patients with CKD and heart failure with reduced ejection fraction but has the added benefit of lower incidence of hyperkalemia<sup><a href="#ref-40">40</a></sup>. ARTS-DN was a multicenter, randomized trial designed to compare the effects of finerenone 1.25 to 20 mg once daily with placebo when added to the standard of care with an RAAS blocker. Patients with type 2 diabetes mellitus, persistent albuminuria (urine albumin-to-creatinine ratio [UACR] of at least 30 mg/g), and eGFR of more than 30 mL/minute per 1.73 m<sup>2</sup> receiving treatment with the minimum recommended dosage of an RAAS blocker prior to the screening visit were included.</p><p class="" id=d1264e766>The primary outcome was the UACR at day 90 compared with baseline. Finerenone reduced UACR in a dose-dependent manner. The placebo-corrected geometric mean UACRs at day 90 to baseline in finerenone 7.5, 10, 15, and 20 mg groups were 0.79 (90% CI 0.68–0.91; <i>P</i> = 0.004), 0.76 (90% CI 0.65–0.88; <i>P</i> = 0.001), 0.67 (90% CI 0.58–0.77; <i>P</i> &lt;0.001), and 0.62 (90% CI 0.54–0.72; <i>P</i> &lt;0.001), respectively. The incidences of an eGFR decrease of at least 40% at any time after baseline were similar in the placebo and finerenone groups, and decreases in eGFR noted in the finerenone groups were reversible 30 days after completion of treatment. There was no reported difference in serious adverse events. This trial demonstrated that, in patients with diabetic nephropathy receiving an ACEI or ARB, adding finerenone compared with placebo improved UACR without an increased risk of hyperkalemia. Longer-term studies are needed to determine whether the addition of finerenone is renoprotective.</p></div><div class=section><a name=d1264e782 class=n-a></a><h3 class=section-title>VA NEPHRON-D trial</h3><p class="" id=d1264e787>The goal of the VA NEPHRON-D (Veterans Affairs Nephropathy in Diabetes) trial<sup><a href="#ref-100">100</a></sup> was to evaluate whether combination treatment with ACEI (lisinopril) and ARB (losartan) compared with ARB alone in patients with diabetic nephropathy slows the progression of CKD. Patients with diabetes, eGFR of 30.0–89.9 mL/minute per 1.73 m<sup>2</sup>, and a UACR of more than 300 mg/g were included. After 2.2 years, the primary outcome of decrease in eGFR, end-stage renal disease, or death occurred in 18.2% of participants in the combination ACEI/ARB group versus 21.0% of the ARB group (HR in combination group of 0.88, 95% CI 0.7–1.12; <i>P</i> = 0.30). There was increased risk for adverse events in the combination group versus ARB alone, including acute kidney injury (18.0% versus 11.0%; <i>P</i> &lt;0.001) and hyperkalemia (9.9% versus 4.4%; <i>P</i> &lt;0.001). The increased risk for adverse events led to early termination of the trial. Combined with the results of ONTARGET, VA NEPHRON-D confirms that there is no benefit but an increased risk of adverse events from dual inhibition from RAAS in high-risk patients.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1264e810>Conclusions</h2><p class="" id=d1264e813>Despite the large number and varying mechanisms of action of existing RAAS-blocking agents, complications such as hyperkalemia and acute kidney injury limit their use. Newer agents that are more specific, such as finerenone, are being developed and may provide the benefits of older RAAS-blocking agents with fewer complications and adverse effects. However, lessons learned from newer agents such as aliskiren indicate that long-term studies with hard end-points are required because outcomes from short-term trials with surrogate outcomes (for example, albuminuria and BNP) may not be consistent with long-term trials with hard clinical end-points. Insight from mechanistic studies and retrospective analyses will inform the design of these trials to target patients most likely to benefit from RAAS blockade, further refining our approach of the use of RAAS blockers in the treatment of HTN.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d1264e1 class=n-a></a><h2 class=main-title id=d1562>Competing interests</h2><p class=metadata-entry><a name=d1264e86 class=n-a></a><p id=d1264e87> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d1264e1 class=n-a></a><h2 class=main-title id=d1564>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d1264e820 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d1880>References</h2><div class="section ref-list"><a name=d1264e820 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d1264e827 class=n-a></a>Gavras H, Brunner HR, Turini GA, <i> et al.</i>: Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. <i>N Engl J Med.</i> 1978; <b>298</b>(18): 991–5. <a target=xrefwindow id=d1264e838 href="http://www.ncbi.nlm.nih.gov/pubmed/205788">PubMed Abstract </a> | <a target=xrefwindow id=d1264e841 href="http://dx.doi.org/10.1056/NEJM197805042981803">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d1264e850 class=n-a></a>Chobanian AV, Bakris GL, Black HR, <i> et al.</i>: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. <i>JAMA.</i> 2003; <b>289</b>(19): 2560–72. <a target=xrefwindow id=d1264e861 href="http://www.ncbi.nlm.nih.gov/pubmed/12748199">PubMed Abstract </a> | <a target=xrefwindow id=d1264e864 href="http://dx.doi.org/10.1001/jama.289.19.2560">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d1264e873 class=n-a></a>Mancia G, De Backer G, Dominiczak A, <i> et al.</i>: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>J Hypertens.</i> 2007; <b>25</b>(6): 1105–87. <a target=xrefwindow id=d1264e884 href="http://www.ncbi.nlm.nih.gov/pubmed/17563527">PubMed Abstract </a> | <a target=xrefwindow id=d1264e887 href="http://dx.doi.org/10.1097/HJH.0b013e3281fc975a">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d1264e896 class=n-a></a>Der Sarkissian S, Huentelman MJ, Stewart J, <i> et al.</i>: ACE2: A novel therapeutic target for cardiovascular diseases. <i>Prog Biophys Mol Biol.</i> 2006; <b>91</b>(1–2): 163–98. <a target=xrefwindow id=d1264e907 href="http://www.ncbi.nlm.nih.gov/pubmed/16009403">PubMed Abstract </a> | <a target=xrefwindow id=d1264e910 href="http://dx.doi.org/10.1016/j.pbiomolbio.2005.05.011">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d1264e919 class=n-a></a>Yusuf S, Sleight P, Pogue J, <i> et al.</i>: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. <i>N Engl J Med.</i> 2000; <b>342</b>(3): 145–53. <a target=xrefwindow id=d1264e930 href="http://www.ncbi.nlm.nih.gov/pubmed/10639539">PubMed Abstract </a> | <a target=xrefwindow id=d1264e933 href="http://dx.doi.org/10.1056/NEJM200001203420301">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d1264e943 class=n-a></a>Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. <i>Lancet.</i> 2000; <b>355</b>(9200): 253–9. <a target=xrefwindow id=d1264e951 href="http://www.ncbi.nlm.nih.gov/pubmed/10675071">PubMed Abstract </a> | <a target=xrefwindow id=d1264e954 href="http://dx.doi.org/10.1016/S0140-6736(99)12323-7">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d1264e963 class=n-a></a>Fox, KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). <i>Lancet.</i> 2003; <b>362</b>(9386): 782–8. <a target=xrefwindow id=d1264e971 href="http://www.ncbi.nlm.nih.gov/pubmed/13678872">PubMed Abstract </a> | <a target=xrefwindow id=d1264e974 href="http://dx.doi.org/10.1016/S0140-6736(03)14286-9">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d1264e983 class=n-a></a>Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. <i>N Engl J Med.</i> 1991; <b>325</b>(5): 293–302. <a target=xrefwindow id=d1264e991 href="http://www.ncbi.nlm.nih.gov/pubmed/2057034">PubMed Abstract </a> | <a target=xrefwindow id=d1264e994 href="http://dx.doi.org/10.1056/NEJM199108013250501">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d1264e1003 class=n-a></a>Hansson L, Lindholm LH, Niskanen L, <i> et al.</i>: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. <i>Lancet.</i> 1999; <b>353</b>(9153): 611–6. <a target=xrefwindow id=d1264e1014 href="http://www.ncbi.nlm.nih.gov/pubmed/10030325">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1017 href="http://dx.doi.org/10.1016/S0140-6736(98)05012-0">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d1264e1026 class=n-a></a>Brenner BM, Cooper ME, de Zeeuw D, <i> et al.</i>: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. <i>N Engl J Med.</i> 2001; <b>345</b>(12): 861–9. <a target=xrefwindow id=d1264e1037 href="http://www.ncbi.nlm.nih.gov/pubmed/11565518">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1040 href="http://dx.doi.org/10.1056/NEJMoa011161">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d1264e1049 class=n-a></a>Lewis EJ, Hunsicker LG, Clarke WR, <i> et al.</i>: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. <i>N Engl J Med.</i> 2001; <b>345</b>(12): 851–60. <a target=xrefwindow id=d1264e1060 href="http://www.ncbi.nlm.nih.gov/pubmed/11565517">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1063 href="http://dx.doi.org/10.1056/NEJMoa011303">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1104759"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e1073 class=n-a></a>ONTARGET Investigators, Yusuf S, Teo KK, <i> et al.</i>: Telmisartan, ramipril, or both in patients at high risk for vascular events. <i>N Engl J Med.</i> 2008; <b>358</b>(15): 1547–59. <a target=xrefwindow id=d1264e1084 href="http://www.ncbi.nlm.nih.gov/pubmed/18378520">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1087 href="http://dx.doi.org/10.1056/NEJMoa0801317">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1104759">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d1264e1100 class=n-a></a>Barnett AH, Bain SC, Bouter P, <i> et al.</i>: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. <i>N Engl J Med.</i> 2004; <b>351</b>(19): 1952–61. <a target=xrefwindow id=d1264e1111 href="http://www.ncbi.nlm.nih.gov/pubmed/15516696">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1114 href="http://dx.doi.org/10.1056/NEJMoa042274">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d1264e1123 class=n-a></a>White WB, Weber MA, Sica D, <i> et al.</i>: Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. <i>Hypertension.</i> 2011; <b>57</b>(3): 413–20. <a target=xrefwindow id=d1264e1134 href="http://www.ncbi.nlm.nih.gov/pubmed/21282560">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1137 href="http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.163402">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d1264e1146 class=n-a></a>Sica D, White WB, Weber MA, <i> et al.</i>: Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. <i>J Clin Hypertens (Greenwich).</i> 2011; <b>13</b>(7): 467–72. <a target=xrefwindow id=d1264e1157 href="http://www.ncbi.nlm.nih.gov/pubmed/21762358">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1160 href="http://dx.doi.org/10.1111/j.1751-7176.2011.00482.x">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d1264e1169 class=n-a></a>Bakris GL, Sica D, Weber M, <i> et al.</i>: The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. <i>J Clin Hypertens (Greenwich).</i> 2011; <b>13</b>(2): 81–8. <a target=xrefwindow id=d1264e1180 href="http://www.ncbi.nlm.nih.gov/pubmed/21272195">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1183 href="http://dx.doi.org/10.1111/j.1751-7176.2010.00425.x">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726206825"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e1192 class=n-a></a>Gitt AK, Bramlage P, Potthoff SA, <i> et al.</i>: Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. <i>BMC Cardiovasc Disord.</i> 2016; <b>16</b>: 56. <a target=xrefwindow id=d1264e1203 href="http://www.ncbi.nlm.nih.gov/pubmed/26956148">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1206 href="http://dx.doi.org/10.1186/s12872-016-0222-6">Publisher Full Text </a> | <a target=xrefwindow id=d1264e1210 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4784379">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726206825">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d1264e1224 class=n-a></a>Kurtz TW, Kajiya T: Differential pharmacology and benefit/risk of azilsartan compared to other sartans. <i>Vasc Health Risk Manag.</i> 2012; <b>8</b>: 133–43. <a target=xrefwindow id=d1264e1232 href="http://www.ncbi.nlm.nih.gov/pubmed/22399858">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1235 href="http://dx.doi.org/10.2147/VHRM.S22595">Publisher Full Text </a> | <a target=xrefwindow id=d1264e1238 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3295635">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d1264e1247 class=n-a></a>Skeggs LT Jr, Kahn JR, Lentz K, <i> et al.</i>: The preparation, purification, and amino acid sequence of a polypeptide renin substrate. <i>J Exp Med.</i> 1957; <b>106</b>(3): 439–53. <a target=xrefwindow id=d1264e1258 href="http://www.ncbi.nlm.nih.gov/pubmed/13463253">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1261 href="http://dx.doi.org/10.1084/jem.106.3.439">Publisher Full Text </a> | <a target=xrefwindow id=d1264e1265 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2136772">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d1264e1274 class=n-a></a>Gradman AH, Kad R: Renin inhibition in hypertension. <i>J Am Coll Cardiol.</i> 2008; <b>51</b>(5): 519–28. <a target=xrefwindow id=d1264e1282 href="http://www.ncbi.nlm.nih.gov/pubmed/18237679">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1285 href="http://dx.doi.org/10.1016/j.jacc.2007.10.027">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d1264e1294 class=n-a></a>Villamil A, Chrysant SG, Calhoun D, <i> et al.</i>: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. <i>J Hypertens.</i> 2007; <b>25</b>(1): 217–26. <a target=xrefwindow id=d1264e1305 href="http://www.ncbi.nlm.nih.gov/pubmed/17143194">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1308 href="http://dx.doi.org/10.1097/HJH.0b013e3280103a6b">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d1264e1317 class=n-a></a>Schmieder RE, Philipp T, Guerediaga J, <i> et al.</i>: Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. <i>Circulation.</i> 2009; <b>119</b>(3): 417–25. <a target=xrefwindow id=d1264e1328 href="http://www.ncbi.nlm.nih.gov/pubmed/19139391">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1331 href="http://dx.doi.org/10.1161/CIRCULATIONAHA.107.750745">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d1264e1340 class=n-a></a>Allikmets K: Aliskiren--an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension. <i>Vasc Health Risk Manag.</i> 2007; <b>3</b>(6): 809–15. <a target=xrefwindow id=d1264e1348 href="http://www.ncbi.nlm.nih.gov/pubmed/18200801">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1351 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2350136">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d1264e1361 class=n-a></a>Nussberger J, Wuerzner G, Jensen C, <i> et al.</i>: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. <i>Hypertension.</i> 2002; <b>39</b>(1): E1–8. <a target=xrefwindow id=d1264e1372 href="http://www.ncbi.nlm.nih.gov/pubmed/11799102">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1375 href="http://dx.doi.org/10.1161/hy0102.102293">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717962604"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e1384 class=n-a></a>Parving HH, Brenner BM, McMurray JJ, <i> et al.</i>: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. <i>N Engl J Med.</i> 2012; <b>367</b>(23): 2204–13. <a target=xrefwindow id=d1264e1395 href="http://www.ncbi.nlm.nih.gov/pubmed/23121378">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1398 href="http://dx.doi.org/10.1056/NEJMoa1208799">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717962604">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726263879"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e1411 class=n-a></a>McMurray JJ, Krum H, Abraham WT, <i> et al.</i>: Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. <i>N Engl J Med.</i> 2016; <b>374</b>(16): 1521–32. <a target=xrefwindow id=d1264e1422 href="http://www.ncbi.nlm.nih.gov/pubmed/27043774">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1425 href="http://dx.doi.org/10.1056/NEJMoa1514859">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726263879">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718097777"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e1438 class=n-a></a>Nicholls SJ, Bakris GL, Kastelein JJ, <i> et al.</i>: Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. <i>JAMA.</i> 2013; <b>310</b>(11): 1135–44. <a target=xrefwindow id=d1264e1449 href="http://www.ncbi.nlm.nih.gov/pubmed/23999933">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1452 href="http://dx.doi.org/10.1001/jama.2013.277169">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718097777">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717988680"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e1465 class=n-a></a>Gheorghiade M, Böhm M, Greene SJ, <i> et al.</i>: Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. <i>JAMA.</i> 2013; <b>309</b>(11): 1125–35. <a target=xrefwindow id=d1264e1476 href="http://www.ncbi.nlm.nih.gov/pubmed/23478743">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1479 href="http://dx.doi.org/10.1001/jama.2013.1954">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717988680">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d1264e1492 class=n-a></a>de Gasparo M, Joss U, Ramjoué HP, <i> et al.</i>: Three new epoxy-spirolactone derivatives: characterization <i>in vivo</i> and <i>in vitro</i>. <i>J Pharmacol Exp Ther.</i> 1987; <b>240</b>(2): 650–6. <a target=xrefwindow id=d1264e1510 href="http://www.ncbi.nlm.nih.gov/pubmed/2949071">PubMed Abstract </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d1264e1520 class=n-a></a>Ménard J: The 45-year story of the development of an anti-aldosterone more specific than spironolactone. <i>Mol Cell Endocrinol.</i> 2004; <b>217</b>(1–2): 45–52. <a target=xrefwindow id=d1264e1528 href="http://www.ncbi.nlm.nih.gov/pubmed/15134800">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1531 href="http://dx.doi.org/10.1016/j.mce.2003.10.008">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d1264e1540 class=n-a></a>Pitt B, Zannad F, Remme WJ, <i> et al.</i>: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. <i>N Engl J Med.</i> 1999; <b>341</b>(10): 709–17. <a target=xrefwindow id=d1264e1551 href="http://www.ncbi.nlm.nih.gov/pubmed/10471456">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1554 href="http://dx.doi.org/10.1056/NEJM199909023411001">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725813579"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e1563 class=n-a></a>Williams B, MacDonald TM, Morant S, <i> et al.</i>: Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. <i>Lancet.</i> 2015; <b>386</b>(10008): 2059–68. <a target=xrefwindow id=d1264e1574 href="http://www.ncbi.nlm.nih.gov/pubmed/26414968">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1577 href="http://dx.doi.org/10.1016/S0140-6736(15)00257-3">Publisher Full Text </a> | <a target=xrefwindow id=d1264e1581 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4655321">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725813579">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d1264e1594 class=n-a></a>White WB, Carr AA, Krause S, <i> et al.</i>: Assessment of the novel selective aldosterone blocker <i>eplerenone</i> using ambulatory and clinical blood pressure in patients with systemic hypertension. <i>Am J Cardiol.</i> 2003; <b>92</b>(1): 38–42. <a target=xrefwindow id=d1264e1608 href="http://www.ncbi.nlm.nih.gov/pubmed/12842242">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1612 href="http://dx.doi.org/10.1016/S0002-9149(03)00461-2">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d1264e1621 class=n-a></a>Williams GH, Burgess E, Kolloch RE, <i> et al.</i>: Efficacy of <i>eplerenone</i> versus <i>enalapril</i> as monotherapy in systemic hypertension. <i>Am J Cardiol.</i> 2004; <b>93</b>(8): 990–6. <a target=xrefwindow id=d1264e1639 href="http://www.ncbi.nlm.nih.gov/pubmed/15081441">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1642 href="http://dx.doi.org/10.1016/j.amjcard.2004.01.007">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d1264e1651 class=n-a></a>Weinberger MH, White WB, Ruilope L, <i> et al.</i>: Effects of eplerenone versus losartan in patients with low-renin hypertension. <i>Am Heart J.</i> 2005; <b>150</b>(3): 426–33. <a target=xrefwindow id=d1264e1662 href="http://www.ncbi.nlm.nih.gov/pubmed/16169319">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1665 href="http://dx.doi.org/10.1016/j.ahj.2004.12.005">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d1264e1675 class=n-a></a>White WB, Duprez D, St Hillaire R , <i> et al.</i>: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. <i>Hypertension.</i> 2003; <b>41</b>(5): 1021–6. <a target=xrefwindow id=d1264e1686 href="http://www.ncbi.nlm.nih.gov/pubmed/12682082">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1689 href="http://dx.doi.org/10.1161/01.HYP.0000067463.13172.EA">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d1264e1698 class=n-a></a>Funder JW: Aldosterone and mineralocorticoid receptors in the cardiovascular system. <i>Prog Cardiovasc Dis.</i> 2010; <b>52</b>(5): 393–400. <a target=xrefwindow id=d1264e1706 href="http://www.ncbi.nlm.nih.gov/pubmed/20226957">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1709 href="http://dx.doi.org/10.1016/j.pcad.2009.12.003">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718308285"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e1718 class=n-a></a>Kolkhof P, Delbeck M, Kretschmer A, <i> et al.</i>: Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. <i>J Cardiovasc Pharmacol.</i> 2014; <b>64</b>(1): 69–78. <a target=xrefwindow id=d1264e1729 href="http://www.ncbi.nlm.nih.gov/pubmed/24621652">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1732 href="http://dx.doi.org/10.1097/FJC.0000000000000091">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718308285">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725708232"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e1745 class=n-a></a>Bärfacker L, Kuhl A, Hillisch A, <i> et al.</i>: Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. <i>ChemMedChem.</i> 2012; <b>7</b>(8): 1385–403. <a target=xrefwindow id=d1264e1756 href="http://www.ncbi.nlm.nih.gov/pubmed/22791416">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1759 href="http://dx.doi.org/10.1002/cmdc.201200081">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725708232">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718013671"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e1772 class=n-a></a>Pitt B, Kober L, Ponikowski P, <i> et al.</i>: Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <i>Eur Heart J.</i> 2013; <b>34</b>(31): 2453–63. <a target=xrefwindow id=d1264e1783 href="http://www.ncbi.nlm.nih.gov/pubmed/23713082">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1786 href="http://dx.doi.org/10.1093/eurheartj/eht187">Publisher Full Text </a> | <a target=xrefwindow id=d1264e1790 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3743070">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718013671">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725851904"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e1803 class=n-a></a>Pitt B, Bakris GL, Bushinsky DA, <i> et al.</i>: Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. <i>Eur J Heart Fail.</i> 2015; <b>17</b>(10): 1057–65. <a target=xrefwindow id=d1264e1814 href="http://www.ncbi.nlm.nih.gov/pubmed/26459796">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1817 href="http://dx.doi.org/10.1002/ejhf.402">Publisher Full Text </a> | <a target=xrefwindow id=d1264e1821 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5057342">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725851904">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726468850"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e1835 class=n-a></a>Weir MR, Bakris GL, Gross C, <i> et al.</i>: Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. <i>Kidney Int.</i> 2016; <b>90</b>(3): 696–704. <a target=xrefwindow id=d1264e1846 href="http://www.ncbi.nlm.nih.gov/pubmed/27350174">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1849 href="http://dx.doi.org/10.1016/j.kint.2016.04.019">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726468850">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725760259"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e1862 class=n-a></a>Bakris GL, Agarwal R, Chan JC, <i> et al.</i>: Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. <i>JAMA.</i> 2015; <b>314</b>(9): 884–94. <a target=xrefwindow id=d1264e1873 href="http://www.ncbi.nlm.nih.gov/pubmed/26325557">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1876 href="http://dx.doi.org/10.1001/jama.2015.10081">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725760259">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d1264e1889 class=n-a></a>Holtkamp FA, de Zeeuw D, de Graeff PA, <i> et al.</i>: Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a <i>post hoc</i> analysis of the combined RENAAL and IDNT trials. <i>Eur Heart J.</i> 2011; <b>32</b>(12): 1493–9. <a target=xrefwindow id=d1264e1903 href="http://www.ncbi.nlm.nih.gov/pubmed/21421598">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1907 href="http://dx.doi.org/10.1093/eurheartj/ehr017">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d1264e1916 class=n-a></a>Amar L, Azizi M, Menard J, <i> et al.</i>: Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. <i>Hypertension.</i> 2010; <b>56</b>(5): 831–8. <a target=xrefwindow id=d1264e1927 href="http://www.ncbi.nlm.nih.gov/pubmed/20837883">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1930 href="http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.157271">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d1264e1939 class=n-a></a>Calhoun DA, White WB, Krum H, <i> et al.</i>: Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. <i>Circulation.</i> 2011; <b>124</b>(18): 1945–55. <a target=xrefwindow id=d1264e1950 href="http://www.ncbi.nlm.nih.gov/pubmed/21986283">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1953 href="http://dx.doi.org/10.1161/CIRCULATIONAHA.111.029892">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d1264e1962 class=n-a></a>Wright JW, Harding JW: Regulatory role of brain angiotensins in the control of physiological and behavioral responses. <i>Brain Res Brain Res Rev.</i> 1992; <b>17</b>(3): 227–62. <a target=xrefwindow id=d1264e1970 href="http://www.ncbi.nlm.nih.gov/pubmed/1361394">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1973 href="http://dx.doi.org/10.1016/0165-0173(92)90018-H">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d1264e1983 class=n-a></a>Basso N, Ruiz P, Kurnjek ML, <i> et al.</i>: The brain renin-angiotensin system and the development of DOC-salt hypertension. <i>Clin Exp Hypertens A.</i> 1985; <b>7</b>(9): 1259–68. <a target=xrefwindow id=d1264e1994 href="http://www.ncbi.nlm.nih.gov/pubmed/3907896">PubMed Abstract </a> | <a target=xrefwindow id=d1264e1997 href="http://dx.doi.org/10.3109/10641968509073589">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d1264e2006 class=n-a></a>Ganten D, Hermann K, Bayer C, <i> et al.</i>: Angiotensin synthesis in the brain and increased turnover in hypertensive rats. <i>Science.</i> 1983; <b>221</b>(4613): 869–71. <a target=xrefwindow id=d1264e2017 href="http://www.ncbi.nlm.nih.gov/pubmed/6879184">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2020 href="http://dx.doi.org/10.1126/science.6879184">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d1264e2029 class=n-a></a>Zini S, Fournie-Zaluski MC, Chauvel E, <i> et al.</i>: Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. <i>Proc Natl Acad Sci U S A.</i> 1996; <b>93</b>(21): 11968–73. <a target=xrefwindow id=d1264e2040 href="http://www.ncbi.nlm.nih.gov/pubmed/8876246">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2043 href="http://dx.doi.org/10.1073/pnas.93.21.11968">Publisher Full Text </a> | <a target=xrefwindow id=d1264e2047 href="http://www.ncbi.nlm.nih.gov/pmc/articles/38167">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d1264e2056 class=n-a></a>Reaux A, Fournie-Zaluski MC, David C, <i> et al.</i>: Aminopeptidase A inhibitors as potential central antihypertensive agents. <i>Proc Natl Acad Sci U S A.</i> 1999; <b>96</b>(23): 13415–20. <a target=xrefwindow id=d1264e2067 href="http://www.ncbi.nlm.nih.gov/pubmed/10557335">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2070 href="http://dx.doi.org/10.1073/pnas.96.23.13415">Publisher Full Text </a> | <a target=xrefwindow id=d1264e2074 href="http://www.ncbi.nlm.nih.gov/pmc/articles/23962">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d1264e2083 class=n-a></a>Reaux A, Fournie-Zaluski MC, Llorens-Cortes C: Angiotensin III: a central regulator of vasopressin release and blood pressure. <i>Trends Endocrinol Metab.</i> 2001; <b>12</b>(4): 157–62. <a target=xrefwindow id=d1264e2091 href="http://www.ncbi.nlm.nih.gov/pubmed/11295571">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2094 href="http://dx.doi.org/10.1016/S1043-2760(01)00381-2">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718212176"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e2103 class=n-a></a>Balavoine F, Azizi M, Bergerot D, <i> et al.</i>: Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug. <i>Clin Pharmacokinet.</i> 2014; <b>53</b>(4): 385–95. <a target=xrefwindow id=d1264e2114 href="http://www.ncbi.nlm.nih.gov/pubmed/24337978">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2117 href="http://dx.doi.org/10.1007/s40262-013-0125-y">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718212176">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d1264e2131 class=n-a></a>Fournie-Zaluski MC, Fassot C, Valentin B, <i> et al.</i>: Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension. <i>Proc Natl Acad Sci U S A.</i> 2004; <b>101</b>(20): 7775–80. <a target=xrefwindow id=d1264e2142 href="http://www.ncbi.nlm.nih.gov/pubmed/15136730">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2145 href="http://dx.doi.org/10.1073/pnas.0402312101">Publisher Full Text </a> | <a target=xrefwindow id=d1264e2149 href="http://www.ncbi.nlm.nih.gov/pmc/articles/419682">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d1264e2158 class=n-a></a>Bodineau L, Frugière A, Marc Y, <i> et al.</i>: Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. <i>Hypertension.</i> 2008; <b>51</b>(5): 1318–25. <a target=xrefwindow id=d1264e2169 href="http://www.ncbi.nlm.nih.gov/pubmed/18362226">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2172 href="http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.098772">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d1264e2181 class=n-a></a>Marc Y, Gao J, Balavoine F, <i> et al.</i>: Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats. <i>Hypertension.</i> 2012; <b>60</b>(2): 411–8. <a target=xrefwindow id=d1264e2192 href="http://www.ncbi.nlm.nih.gov/pubmed/22710644">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2195 href="http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.190942">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725388870"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e2204 class=n-a></a>Te Riet L, van Esch JH, Roks AJ, <i> et al.</i>: Hypertension: renin-angiotensin-aldosterone system alterations. <i>Circ Res.</i> 2015; <b>116</b>(6): 960–75. <a target=xrefwindow id=d1264e2215 href="http://www.ncbi.nlm.nih.gov/pubmed/25767283">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2218 href="http://dx.doi.org/10.1161/CIRCRESAHA.116.303587">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725388870">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d1264e2231 class=n-a></a>Do TH, Chen Y, Nguyen VT, <i> et al.</i>: Vaccines in the management of hypertension. <i>Expert Opin Biol Ther.</i> 2010; <b>10</b>(7): 1077–87. <a target=xrefwindow id=d1264e2242 href="http://www.ncbi.nlm.nih.gov/pubmed/20455790">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2245 href="http://dx.doi.org/10.1517/14712598.2010.487060">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d1264e2254 class=n-a></a>Laragh JH, Sealey JE: The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. <i>Am J Hypertens.</i> 2011; <b>24</b>(11): 1164–80. <a target=xrefwindow id=d1264e2262 href="http://www.ncbi.nlm.nih.gov/pubmed/21938070">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2265 href="http://dx.doi.org/10.1038/ajh.2011.171">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d1264e2275 class=n-a></a>Turner ST, Schwartz GL, Chapman AB, <i> et al.</i>: Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. <i>Am J Hypertens.</i> 2010; <b>23</b>(9): 1014–22. <a target=xrefwindow id=d1264e2286 href="http://www.ncbi.nlm.nih.gov/pubmed/20725057">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2289 href="http://dx.doi.org/10.1038/ajh.2010.98">Publisher Full Text </a> | <a target=xrefwindow id=d1264e2293 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2941699">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d1264e2302 class=n-a></a>Alderman MH, Cohen HW, Sealey JE, <i> et al.</i>: Pressor responses to antihypertensive drug types. <i>Am J Hypertens.</i> 2010; <b>23</b>(9): 1031–7. <a target=xrefwindow id=d1264e2313 href="http://www.ncbi.nlm.nih.gov/pubmed/20725055">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2316 href="http://dx.doi.org/10.1038/ajh.2010.114">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727373788"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e2325 class=n-a></a>Tu W, Eckert GJ, Pratt JH, <i> et al.</i>: Plasma levels of prorenin and renin in blacks and whites: their relative abundance and associations with plasma aldosterone concentration. <i>Am J Hypertens.</i> 2012; <b>25</b>(9): 1030–4. <a target=xrefwindow id=d1264e2336 href="http://www.ncbi.nlm.nih.gov/pubmed/22695510">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2339 href="http://dx.doi.org/10.1038/ajh.2012.83">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727373788">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d1264e2352 class=n-a></a>Sealey JE, Laragh JH: Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. <i>Am J Hypertens.</i> 2009; <b>22</b>(1): 112–21. <a target=xrefwindow id=d1264e2360 href="http://www.ncbi.nlm.nih.gov/pubmed/18802434">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2363 href="http://dx.doi.org/10.1038/ajh.2008.275">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d1264e2372 class=n-a></a>Egan BM, Basile JN, Rehman SU, <i> et al.</i>: Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. <i>Am J Hypertens.</i> 2009; <b>22</b>(7): 792–801. <a target=xrefwindow id=d1264e2383 href="http://www.ncbi.nlm.nih.gov/pubmed/19373213">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2386 href="http://dx.doi.org/10.1038/ajh.2009.63">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d1264e2395 class=n-a></a>Sim JJ, Bhandari SK, Shi J, <i> et al.</i>: Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system. <i>Am J Hypertens.</i> 2012; <b>25</b>(3): 379–88. <a target=xrefwindow id=d1264e2406 href="http://www.ncbi.nlm.nih.gov/pubmed/22158065">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2409 href="http://dx.doi.org/10.1038/ajh.2011.216">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d1264e2419 class=n-a></a>de Wardener HE, He FJ, MacGregor GA: Plasma sodium and hypertension. <i>Kidney Int.</i> 2004; <b>66</b>(6): 2454–66. <a target=xrefwindow id=d1264e2427 href="http://www.ncbi.nlm.nih.gov/pubmed/15569339">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2430 href="http://dx.doi.org/10.1111/j.1523-1755.2004.66018.x">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d1264e2439 class=n-a></a>Titze J, Machnik A: Sodium sensing in the interstitium and relationship to hypertension. <i>Curr Opin Nephrol Hypertens.</i> 2010; <b>19</b>(4): 385–92. <a target=xrefwindow id=d1264e2447 href="http://www.ncbi.nlm.nih.gov/pubmed/20571401">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2450 href="http://dx.doi.org/10.1097/MNH.0b013e32833aeb3b">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13352973"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e2459 class=n-a></a>Schmidlin O, Forman A, Leone A, <i> et al.</i>: Salt sensitivity in blacks: evidence that the initial pressor effect of NaCl involves inhibition of vasodilatation by asymmetrical dimethylarginine. <i>Hypertension.</i> 2011; <b>58</b>(3): 380–5. <a target=xrefwindow id=d1264e2470 href="http://www.ncbi.nlm.nih.gov/pubmed/21788605">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2473 href="http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.170175">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13352973">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d1264e2486 class=n-a></a>Ying WZ, Sanders PW: Dietary salt intake activates MAP kinases in the rat kidney. <i>FASEB J.</i> 2002; <b>16</b>(12): 1683–4. <a target=xrefwindow id=d1264e2494 href="http://www.ncbi.nlm.nih.gov/pubmed/12206991">PubMed Abstract </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d1264e2503 class=n-a></a>Chandramohan G, Bai Y, Norris K, <i> et al.</i>: Effects of dietary salt on intrarenal angiotensin system, NAD(P)H oxidase, COX-2, MCP-1 and PAI-1 expressions and NF-kappaB activity in salt-sensitive and -resistant rat kidneys. <i>Am J Nephrol.</i> 2008; <b>28</b>(1): 158–67. <a target=xrefwindow id=d1264e2514 href="http://www.ncbi.nlm.nih.gov/pubmed/17951998">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2517 href="http://dx.doi.org/10.1159/000110021">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d1264e2526 class=n-a></a>Susic D, Zhou X, Frohlich ED: Angiotensin blockade prevents salt-induced injury of the renal circulation in spontaneously hypertensive rats. <i>Am J Nephrol.</i> 2009; <b>29</b>(6): 639–45. <a target=xrefwindow id=d1264e2534 href="http://www.ncbi.nlm.nih.gov/pubmed/19155618">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2537 href="http://dx.doi.org/10.1159/000195633">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d1264e2547 class=n-a></a>Varagic J, Frohlich ED, Susic D, <i> et al.</i>: AT<sub>1</sub> receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure. <i>Am J Physiol Heart Circ Physiol.</i> 2008; <b>294</b>(2): H853–8. <a target=xrefwindow id=d1264e2561 href="http://www.ncbi.nlm.nih.gov/pubmed/18055516">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2565 href="http://dx.doi.org/10.1152/ajpheart.00737.2007">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d1264e2574 class=n-a></a>Susic D, Frohlich ED, Kobori H, <i> et al.</i>: Salt-induced renal injury in SHRs is mediated by AT1 receptor activation. <i>J Hypertens.</i> 2011; <b>29</b>(4): 716–23. <a target=xrefwindow id=d1264e2585 href="http://www.ncbi.nlm.nih.gov/pubmed/21346625">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2588 href="http://dx.doi.org/10.1097/HJH.0b013e3283440683">Publisher Full Text </a> | <a target=xrefwindow id=d1264e2592 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3053430">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d1264e2601 class=n-a></a>Kobori H, Nishiyama A, Abe Y, <i> et al.</i>: Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. <i>Hypertension.</i> 2003; <b>41</b>(3): 592–7. <a target=xrefwindow id=d1264e2612 href="http://www.ncbi.nlm.nih.gov/pubmed/12623964">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2615 href="http://dx.doi.org/10.1161/01.HYP.0000056768.03657.B4">Publisher Full Text </a> | <a target=xrefwindow id=d1264e2619 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2572575">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1025723"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e2628 class=n-a></a>Jaffe IZ, Mendelsohn ME: Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. <i>Circ Res.</i> 2005; <b>96</b>(6): 643–50. <a target=xrefwindow id=d1264e2636 href="http://www.ncbi.nlm.nih.gov/pubmed/15718497">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2639 href="http://dx.doi.org/10.1161/01.RES.0000159937.05502.d1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1025723">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d1264e2652 class=n-a></a>Fujita T: Aldosterone in salt-sensitive hypertension and metabolic syndrome. <i>J Mol Med (Berl).</i> 2008; <b>86</b>(6): 729–34. <a target=xrefwindow id=d1264e2660 href="http://www.ncbi.nlm.nih.gov/pubmed/18437332">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2663 href="http://dx.doi.org/10.1007/s00109-008-0343-1">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1131878"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e2672 class=n-a></a>Shibata S, Nagase M, Yoshida S, <i> et al.</i>: Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. <i>Nat Med.</i> 2008; <b>14</b>(12): 1370–6. <a target=xrefwindow id=d1264e2683 href="http://www.ncbi.nlm.nih.gov/pubmed/19029984">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2686 href="http://dx.doi.org/10.1038/nm.1879">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1131878">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d1264e2700 class=n-a></a>Ghazi L, Dudenbostel T, Lin CP, <i> et al.</i>: Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. <i>J Hypertens.</i> 2016; <b>34</b>(5): 1005–10. <a target=xrefwindow id=d1264e2711 href="http://www.ncbi.nlm.nih.gov/pubmed/26886564">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2714 href="http://dx.doi.org/10.1097/HJH.0000000000000870">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d1264e2723 class=n-a></a>Cruickshank JK, Anderson NM, Wadsworth J, <i> et al.</i>: Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. <i>BMJ.</i> 1988; <b>297</b>(6657): 1155–9. <a target=xrefwindow id=d1264e2734 href="http://www.ncbi.nlm.nih.gov/pubmed/3144329">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2737 href="http://dx.doi.org/10.1136/bmj.297.6657.1155">Publisher Full Text </a> | <a target=xrefwindow id=d1264e2741 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1835009">Free Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d1264e2750 class=n-a></a>Preston RA, Materson BJ, Reda DJ, <i> et al.</i>: Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. <i>JAMA.</i> 1998; <b>280</b>(13): 1168–72. <a target=xrefwindow id=d1264e2761 href="http://www.ncbi.nlm.nih.gov/pubmed/9777817">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2764 href="http://dx.doi.org/10.1001/jama.280.13.1168">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725125555"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e2773 class=n-a></a>Weir MR, Chrysant SG, McCarron DA, <i> et al.</i>: Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. <i>Hypertension.</i> 1998; <b>31</b>(5): 1088–96. <a target=xrefwindow id=d1264e2784 href="http://www.ncbi.nlm.nih.gov/pubmed/9576119">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2787 href="http://dx.doi.org/10.1161/01.HYP.31.5.1088">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725125555">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d1264e2800 class=n-a></a>Helmer OM: The renin-angiotensin system and its relation to hypertension. <i>Prog Cardiovasc Dis.</i> 1965; <b>8</b>(2): 117–28. <a target=xrefwindow id=d1264e2808 href="http://www.ncbi.nlm.nih.gov/pubmed/4283886">PubMed Abstract </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d1264e2817 class=n-a></a>Chrysant SG, Danisa K, Kem DC, <i> et al.</i>: Racial differences in pressure, volume and renin interrelationships in essential hypertension. <i>Hypertension.</i> 1979; <b>1</b>(2): 136–41. <a target=xrefwindow id=d1264e2828 href="http://www.ncbi.nlm.nih.gov/pubmed/399939">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2831 href="http://dx.doi.org/10.1161/01.HYP.1.2.136">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d1264e2841 class=n-a></a>Oparil S: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications. <i>Hypertension.</i> 2003; <b>41</b>(5): 1006–9. <a target=xrefwindow id=d1264e2849 href="http://www.ncbi.nlm.nih.gov/pubmed/12695423">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2852 href="http://dx.doi.org/10.1161/01.HYP.0000070905.09395.F6">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d1264e2861 class=n-a></a>ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>JAMA.</i> 2002; <b>288</b>(23): 2981–97. <a target=xrefwindow id=d1264e2869 href="http://www.ncbi.nlm.nih.gov/pubmed/12479763">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2872 href="http://dx.doi.org/10.1001/jama.288.23.2981">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d1264e2881 class=n-a></a>Gupta AK, Poulter NR, Dobson J, <i> et al.</i>: Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial. <i>Am J Hypertens.</i> 2010; <b>23</b>(9): 1023–30. <a target=xrefwindow id=d1264e2892 href="http://www.ncbi.nlm.nih.gov/pubmed/20725056">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2895 href="http://dx.doi.org/10.1038/ajh.2010.105">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d1264e2904 class=n-a></a>Saha C, Eckert GJ, Ambrosius WT, <i> et al.</i>: Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. <i>Hypertension.</i> 2005; <b>46</b>(3): 481–7. <a target=xrefwindow id=d1264e2915 href="http://www.ncbi.nlm.nih.gov/pubmed/16116042">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2918 href="http://dx.doi.org/10.1161/01.HYP.0000179582.42830.1d">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d1264e2927 class=n-a></a>Flack JM, Oparil S, Pratt JH, <i> et al.</i>: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. <i>J Am Coll Cardiol.</i> 2003; <b>41</b>(7): 1148–55. <a target=xrefwindow id=d1264e2938 href="http://www.ncbi.nlm.nih.gov/pubmed/12679215">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2941 href="http://dx.doi.org/10.1016/S0735-1097(03)00054-8">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d1264e2950 class=n-a></a>Cavallari LH, Fashingbauer LA, Beitelshees AL, <i> et al.</i>: Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. <i>Pharmacotherapy.</i> 2004; <b>24</b>(6): 750–6. <a target=xrefwindow id=d1264e2961 href="http://www.ncbi.nlm.nih.gov/pubmed/15222665">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2964 href="http://dx.doi.org/10.1592/phco.24.8.750.36076">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725555236"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e2974 class=n-a></a>Bangalore S, Ogedegbe G, Gyamfi J, <i> et al.</i>: Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks. <i>Am J Med.</i> 2015; <b>128</b>(11): 1195–203. <a target=xrefwindow id=d1264e2985 href="http://www.ncbi.nlm.nih.gov/pubmed/26071821">PubMed Abstract </a> | <a target=xrefwindow id=d1264e2988 href="http://dx.doi.org/10.1016/j.amjmed.2015.04.034">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725555236">F1000 Recommendation</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727373789"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e3001 class=n-a></a>Peck RN, Smart LR, Beier R, <i> et al.</i>: Difference in blood pressure response to ACE-Inhibitor monotherapy between black and white adults with arterial hypertension: a meta-analysis of 13 clinical trials. <i>BMC Nephrol.</i> 2013; <b>14</b>: 201. <a target=xrefwindow id=d1264e3012 href="http://www.ncbi.nlm.nih.gov/pubmed/24067062">PubMed Abstract </a> | <a target=xrefwindow id=d1264e3015 href="http://dx.doi.org/10.1186/1471-2369-14-201">Publisher Full Text </a> | <a target=xrefwindow id=d1264e3019 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3849838">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727373789">F1000 Recommendation</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d1264e3032 class=n-a></a>Ely DL, Turner ME: Hypertension in the spontaneously hypertensive rat is linked to the Y chromosome. <i>Hypertension.</i> 1990; <b>16</b>(3): 277–81. <a target=xrefwindow id=d1264e3040 href="http://www.ncbi.nlm.nih.gov/pubmed/2394486">PubMed Abstract </a> | <a target=xrefwindow id=d1264e3043 href="http://dx.doi.org/10.1161/01.HYP.16.3.277">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d1264e3052 class=n-a></a>Arnold AP, Chen X: What does the "four core genotypes" mouse model tell us about sex differences in the brain and other tissues? <i>Front Neuroendocrinol.</i> 2009; <b>30</b>(1): 1–9. <a target=xrefwindow id=d1264e3060 href="http://www.ncbi.nlm.nih.gov/pubmed/19028515">PubMed Abstract </a> | <a target=xrefwindow id=d1264e3063 href="http://dx.doi.org/10.1016/j.yfrne.2008.11.001">Publisher Full Text </a> | <a target=xrefwindow id=d1264e3066 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3282561">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d1264e3075 class=n-a></a>Ji H, Zheng W, Wu X, <i> et al.</i>: Sex chromosome effects unmasked in angiotensin II-induced hypertension. <i>Hypertension.</i> 2010; <b>55</b>(5): 1275–82. <a target=xrefwindow id=d1264e3086 href="http://www.ncbi.nlm.nih.gov/pubmed/20231528">PubMed Abstract </a> | <a target=xrefwindow id=d1264e3089 href="http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.144949">Publisher Full Text </a> | <a target=xrefwindow id=d1264e3093 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2905778">Free Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d1264e3102 class=n-a></a>Schunkert H, Danser AH, Hense HW, <i> et al.</i>: Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. <i>Circulation.</i> 1997; <b>95</b>(1): 39–45. <a target=xrefwindow id=d1264e3113 href="http://www.ncbi.nlm.nih.gov/pubmed/8994414">PubMed Abstract </a> | <a target=xrefwindow id=d1264e3116 href="http://dx.doi.org/10.1161/01.CIR.95.1.39">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d1264e3126 class=n-a></a>Hilliard LM, Sampson AK, Brown RD, <i> et al.</i>: The "his and hers" of the renin-angiotensin system. <i>Curr Hypertens Rep.</i> 2013; <b>15</b>(1): 71–9. <a target=xrefwindow id=d1264e3137 href="http://www.ncbi.nlm.nih.gov/pubmed/23180053">PubMed Abstract </a> | <a target=xrefwindow id=d1264e3140 href="http://dx.doi.org/10.1007/s11906-012-0319-y">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d1264e3149 class=n-a></a>Miller JA, Cherney DZ, Duncan JA, <i> et al.</i>: Gender differences in the renal response to renin-angiotensin system blockade. <i>J Am Soc Nephrol.</i> 2006; <b>17</b>(9): 2554–60. <a target=xrefwindow id=d1264e3160 href="http://www.ncbi.nlm.nih.gov/pubmed/16914541">PubMed Abstract </a> | <a target=xrefwindow id=d1264e3163 href="http://dx.doi.org/10.1681/ASN.2005101095">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d1264e3172 class=n-a></a>Hudson M, Rahme E, Behlouli H, <i> et al.</i>: Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure--a population study. <i>Eur J Heart Fail.</i> 2007; <b>9</b>(6–7): 602–9. <a target=xrefwindow id=d1264e3183 href="http://www.ncbi.nlm.nih.gov/pubmed/17383932">PubMed Abstract </a> | <a target=xrefwindow id=d1264e3186 href="http://dx.doi.org/10.1016/j.ejheart.2007.02.001">Publisher Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718430864"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e3195 class=n-a></a>Gueyffier F, Subtil F, Bejan-Angoulvant T, <i> et al.</i>: Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial. <i>J Hum Hypertens.</i> 2015; <b>29</b>(1): 22–7. <a target=xrefwindow id=d1264e3206 href="http://www.ncbi.nlm.nih.gov/pubmed/24739801">PubMed Abstract </a> | <a target=xrefwindow id=d1264e3209 href="http://dx.doi.org/10.1038/jhh.2014.29">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718430864">F1000 Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718171017"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1264e3222 class=n-a></a>Fried LF, Emanuele N, Zhang JH, <i> et al.</i>: Combined angiotensin inhibition for the treatment of diabetic nephropathy. <i>N Engl J Med.</i> 2013; <b>369</b>(20): 1892–903. <a target=xrefwindow id=d1264e3233 href="http://www.ncbi.nlm.nih.gov/pubmed/24206457">PubMed Abstract </a> | <a target=xrefwindow id=d1264e3236 href="http://dx.doi.org/10.1056/NEJMoa1303154">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718171017">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 21 Mar 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-297.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-297.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Division of Renal Disease and Hypertension, Department of Medicine, University of Minnesota, Minnesota, MN, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-297/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 21 Mar 2017, 6:297 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.9692.1">https://doi.org/10.12688/f1000research.9692.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Ghazi L and Drawz P. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the <a href="http://creativecommons.org/publicdomain/zero/1.0/" target=_blank data-test-id=box-data-licence-link>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication). </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=10445 data-id=9692 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9692.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-297/v1/pdf?article_uuid=3e801393-96ec-496a-8e79-0f7581b68a78" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.9692.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Ghazi L and Drawz P. Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy [version 1; peer review: 3 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):297 (<a href="https://doi.org/10.12688/f1000research.9692.1" target=_blank>https://doi.org/10.12688/f1000research.9692.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=9692 id=mobile-track-article-signin-9692 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9692?target=/articles/6-297.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10445 /> <input name=articleId type=hidden value=9692 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>AK Johnson</strong>, Department of Psychological and Brain Sciences, University of Iowa, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Anton van den Meiracker</strong>, Department of Internal Medicine, Erasmus Medical Centre, The Netherlands </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Bertram Pitt</strong>, University of Michigan School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 21 Mar 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-297.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-297.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=21030-20755></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=21029-20754></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=21031-20756></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-297/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>21 Mar 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>AK Johnson</strong>, Department of Psychological and Brain Sciences, University of Iowa, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Anton van den Meiracker</strong>, Department of Internal Medicine, Erasmus Medical Centre, The Netherlands </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Bertram Pitt</strong>, University of Michigan School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-297.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-297/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Advances in understanding the renin-angiotensin-aldosterone...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-297/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-297/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-297/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Ghazi L and Drawz P');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-297/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-297",
            templates : {
                twitter : "Advances in understanding the renin-angiotensin-aldosterone system.... Ghazi L and Drawz P, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-297/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/9692/10445")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "10445");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "20754": 0,
                           "20755": 0,
                           "20756": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "6e2b125a-f970-44c5-894a-6b740bf4d37f";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-297.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-297.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-297.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-297.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-297.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>